Press release
Primary Sclerosing Cholangitis Market | Exploring Current Trends and Growth Status - CAGR : 7.4%
Primary Sclerosing Cholangitis Market
The Primary Sclerosing Cholangitis market is projected to grow at a CAGR of 7.4% through 2031.
Request a Free Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://datamintelligence.com/download-sample/primary-sclerosing-cholangitis-market?sv
Market opportunities and Growth Drivers:
The rising prevalence of Primary Sclerosing Cholangitis (PSC), particularly among individuals with Inflammatory Bowel Disease (IBD), is driving demand for earlier diagnosis and more effective treatment options, highlighting a significant unmet need in the healthcare landscape. Coupled with increasing research initiatives and AI-driven clinical trial innovations, there is substantial opportunity for biotech firms to develop targeted therapies and expand access in underserved populations.
Primary Sclerosing Cholangitis Market Recent Development:
In July 2023, Galmed Pharmaceuticals partnered with OnKai to launch an AI-powered clinical trial program focused on improving PSC research participation in underserved communities, using smart-grid technology and tailored enrollment models.
OnKai's Smart-Grid AI Platform is now being implemented in local clinics as a pilot, offering support infrastructure and incentives to ensure inclusive and equitable clinical trial participation for PSC treatment development.
List of the Key Players in the Primary Sclerosing Cholangitis Market:
Intercept Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Johnson & Johnson, Allergan, Genfit, Pliant Therapeutics, ChemomAb Therapeutics Ltd., and Dr. Falk Pharma among others.
Assessing the Effects of U.S. Tariffs on the Primary Sclerosing Cholangitis Market
The U.S. tariff war is reshaping how businesses analyze trends and make strategic decisions. As tariffs drive up costs and disrupt supply chains, companies are increasingly focused on understanding consumer behavior, identifying new sourcing opportunities, and adjusting their operations to remain competitive. The ongoing uncertainty has created a stronger demand for timely insights and data-driven strategies to navigate shifting trade dynamics and economic pressures.
Research Process:
Both primary and secondary data sources have been used in the global Primary Sclerosing Cholangitis Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/primary-sclerosing-cholangitis-market?sv
Segment Covered in the Primary Sclerosing Cholangitis Market:
By Treatment: Medication-based Therapies, Bile Duct Blockages, Liver Transplantation
By Disease Stage: Early-stage PSC, Moderate-stage PSC, Advanced-stage PSC
By Patient Age: Child (0-18), Adult (18 and above)
By End-User: Hospitals, Specialty Clinics, Others
Regional Analysis for Primary Sclerosing Cholangitis Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
People Also Ask:
Most Frequently Asked Questions in the Primary Sclerosing Cholangitis Market Research Industry:
➠ What are the global figures for sales, production, consumption, imports, and exports in the Primary Sclerosing Cholangitis market?
➠ Who are the top manufacturers in the global Primary Sclerosing Cholangitis industry, and what is their current status in terms of production capacity, output, sales performance, pricing structure, cost analysis, profit margins, and overall revenue?
➠ What key opportunities are available for vendors in the Primary Sclerosing Cholangitis market, and what challenges are they likely to encounter?
➠ Which application areas, end-user segments, or product types are projected to experience significant growth, and how is the market share distributed among them?
➠ What are the major drivers and barriers influencing the growth trajectory of the Primary Sclerosing Cholangitis market?
➠ What are the primary sales, marketing, and distribution strategies used across the global Primary Sclerosing Cholangitis industry landscape?
Browse More Reports: https://www.datamintelligence.com/research-report/primary-sclerosing-cholangitis-market?sv
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Market | Exploring Current Trends and Growth Status - CAGR : 7.4% here
News-ID: 4020153 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Hyperammonemia Market 2025 | Growth Drivers, Trends & Market Forec …
Market Size and Growth
Global Hyperammonemia Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.
Key Development:
United States: Recent Industry Developments
✅ July 2025: Amogy secured an additional $23 million in venture financing, bringing its total funding to $80 million. This investment aims to accelerate the company's growth and advance its ammonia-to-power solutions.
✅ July 2025: Navigator Gas announced a joint venture with Amon Maritime to construct two ammonia-fueled…
United States Internet of Things (IoT) in Agriculture Market 2025 | Growth Drive …
Market Size and Growth
Global Internet of Things (IoT) in Agriculture Market reached US$ 31.10 billion in 2023 and is expected to reach US$ 83.26 billion by 2031, growing with a CAGR of 13.1% during the forecast period 2024-2031.
Recent Mergers and Acquisitions:
United States:
✅ In Sep 2025, Sensei Farms (U.S.), backed by Larry Ellison, acquired ~25 acres in Lockhart, Texas - the former facility of robotics-farming company Iron Ox. While…
United States Medical Device Coatings Market 2025 | Growth Drivers, Key Players …
Market Size and Growth
Medical device coatings market is growing at a High CAGR during the forecast period 2024-2031.
Recent Mergers and Acquisitions:
United States: Recent Medical Device Coatings Developments
✅ In April 2025, the FDA granted 510(k) clearance to Becton Dickinson's CentroVena One central venous catheter, which features an advanced hydrophilic coating to improve device performance.
✅ In March 2025, the U.S. FTC filed suit to block GTCR's planned $627M acquisition of Surmodics…
United States Nephrotic Syndrome Drugs Market 2025 | Growth Drivers, Trends & Ma …
Market Size and Growth
The global nephrotic syndrome drugs market reached US$ 423.7 million in 2023 and is expected to reach US$ 645.3 million by 2030, growing with a CAGR of 5.4% during the forecast period 2024-2031.
Recent Mergers and Acquisitions:
United States:
✅ In June 2025, Biogen initiated a Phase 3 study of felzartamab for the treatment of primary membranous nephropathy, a common cause of nephrotic syndrome. This trial aims to…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
